An interview with Ranbaxy CEO and MD Arun Sawhney on the changes in the past four years and how the company plans to address the US concerns.
Japanese electronics major sources 60% of requirement from India.
The company will lose the validity of its licences in Kolkata, West Bengal and Mumbai telecom circles on in January.
SFIO official refuses to reveal the nature of additional charges found during investigation.
Sharad Pawar says final draft will go to Cabinet before Tuesday.
Company refuses to comment, says 'matters internal to organisation'
Action is hotting up in the telecom space, with Russian giant Sistema in preliminary discussions with Aircel to pick up an equity stake.
Another cap for imported insulin; domestic manufacturers cry foul.
Though reserve for CDMA, there were no bidders for the spectrum in the recent auction. GSM operators could buy it to launch 4G and 3G services.
Airtel operates as Airtel-Vodafone in Jersey and Guernsey to offer Vodafone trademarks in the British Channel Islands.
FinMin had objected and wanted existing cost-plus method retained.
CCI to examine competition part of deals, RBI prudential aspects.
Work to begin after that on corrective measures to meet US regulator's requirements.
After refarming, over 142.5 MHz of spectrum is expected to be available for auctioning next year.
A source with knowledge of the matter claimed Dabur might have already approached the two companies, without revealing further details.
USFDA has extended the timeline for granting tentative approval to generic drug applications filed under Para IV of its rules by 10 months.
With bouyant demand in domestic market, increasing exports, the co would need to set up a second manufacturing plant in about three years.
Bharti Infratel is a provider of telecom towers and related infrastructure and on a consolidated basis, is one of the largest in India, "based on the number of towers that Bharti Infratel owns and operates and the number of towers owned or operated by Indus, that are represented by Bharti Infratel's 42 per cent equity interest in Indus," according to the offer document.
Market leader with 20.6% share in the air conditioning segment.
Sun Pharma could have to withdraw cancer drug as J&J re-enters after temporary eclipse
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances